Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Essilor International    EI   FR0000121667

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

ESSILOR INTL. : Essilor Continues to Expand in the United States

share with twitter share with LinkedIn share with facebook
share via e-mail
01/31/2013 | 06:35am CET

Regulatory News:

Essilor (Paris:EI) is continuing to strengthen its positions in the United States, the world's leading market for ophthalmic lenses, with the acquisition of a lens manufacturer and a new prescription laboratory.

The Company has announced the acquisition of an 80% share in X-Cel Optical, a manufacturer of ophthalmic lenses based in Minnesota (US). Leveraging its widely recognized, high performance technical expertise, X-Cel Optical offers a wide range of niche products, the vast majority of which are bi- and tri-focal, stock and variable-tint lenses. The line-ups are produced in various materials, including Trivex?. With a refraction index of 1.53 and impact resistance comparable to that of polycarbonate, Trivex? is enjoying rapid sales growth.

X-Cel Optical produces just over two million lenses a year and generates full-year revenue of approximately $33 million.

The development of the X-Cel Optical product line, which fits very well with Essilor's, will be led by the Group's various distribution networks in the United States, comprising both proprietary and independent laboratories, and around the world. The X-Cel Optical offer may also be moved upmarket, using Essilor's leading-edge technologies, in particular the Crizal® range of surface coatings, as a lever.

In addition, the partnership will enable Essilor to optimize its sourcing strategy. Lastly, Essilor and X-Cel Optical may also share their engineering skills and capabilities to optimize their production processes.

Essilor is also continuing to deepen its local distribution network in the United States to capture the market's growth potential for value-added lenses. The Company has signed a partnership with Lenstech Optical, a prescription laboratory in Indiana that generates annual revenue of $6 million.

In the future, Essilor will activate the usual value-creation levers by providing Lenstech Optical with new technologies that will speed the distribution of its flagship brands, including Varilux® and Crizal®, in the partner's catchment area.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around ?150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog? and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of ?4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and
Financial Communication
Véronique Gillet ? Sébastien Leroy ? Ariel Bauer
Phone: +33 (0)1 49 77 42 16
Media Relations
Maïlis Thiercelin
Phone: +33 (0)1 49 77 45 02

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
01/19 ESSILOR INTERNATIONAL : Patent Issued for Method for Assisting Visual Exploratio..
01/04 ESSILOR INTERNATIONAL : "Method Implemented by Computer Means for Calculating a ..
2017 ESSILOR INTERNATIONAL : Researchers Submit Patent Application, "Systems and Meth..
2017 ESSILOR INTERNATIONAL : "A Method for Adapting the Sensorial Output Mode of a Se..
2017 ESSILOR INTERNATIONAL : Awarded grand prix for employee shareholding initiatives
2017 ESSILOR INTERNATIONAL : Luxottica CEO exits eyewear giant ahead of Essilor merge..
2017 EXCLUSIVE : Luxottica, Essilor tie-up on track for unconditional EU okay - sourc..
2017 ESSILOR - NEWS RELEASE : Capital Increase Reserved for Employees
2017 ESSILOR - NEWS RELEASE : Capital Increase Reserved for Employees
2017 ESSILOR INTERNATIONAL : Luxottica Group Will Have New CEO, Says Chief -FT
More news
News from SeekingAlpha
2017 Essilor International (ESLOF) Q3 2017 Results - Earnings Call Transcript
2017 Essilor International SA reports Q3 results
2017 EU launches full investigation into Essilor-Luxottica merger
2017 EU regulators to review Luxottica-Essilor merger
2017 Lack Of Takeovers Sees Medtech Hiring Staff Again
Financials (€)
Sales 2017 7 497 M
EBIT 2017 1 321 M
Net income 2017 835 M
Debt 2017 1 873 M
Yield 2017 1,35%
P/E ratio 2017 29,13
P/E ratio 2018 26,67
EV / Sales 2017 3,52x
EV / Sales 2018 3,32x
Capitalization 24 553 M
Duration : Period :
Essilor International Technical Analysis Chart | EI | FR0000121667 | 4-Traders
Technical analysis trends ESSILOR INTERNATIONAL
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 120 €
Spread / Average Target 7,0%
EPS Revisions
Hubert Sagnières Chairman & Chief Executive Officer
Laurent Vacherot President, Co-Chief Operating Officer & Director
Paul du Saillant Co-Chief Operating Officer
Jean Carrier-Guillomet Co-Chief Operating Officer
Hilary Halper Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MENICON CO LTD-5.14%1 012
INTEROJO CO. LTD.--.--%481